Search - tctmd.com

Displaying 1 - 20 of 110

Sort: Relevancy | Date

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

Todd Neale

October 07, 2025

News Opinion Editor's Corner

TCTMD's Top 10 Most Popular Stories for August 2025

Caitlin E. Cox

August 28, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

L.A. McKeown

July 14, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

Shelley Wood

October 01, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

L.A. McKeown

August 31, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

L.A. McKeown

June 18, 2024

News Daily News

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

Todd Neale

January 04, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Advertisement

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

TCTMD's Top 10 Most Popular Stories for August 2025

DAPT De-escalation Success Varies by Sex: Meta-analysis

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

FDA Approves Triple Therapy Polypill for High Blood Pressure

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

TCTMD’s Top 10 Most Popular Stories for September 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Polypills Show Promise in Diverse Hypertensive Patient Groups

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content